logo
Book a meeting
GCANRx

Gcan Rx

Biotechnology, 15 Walker Ave, Baltimore, Maryland, 33130, United States, 1-10 Employees

gcanrx.com

  • LinkedIn

Who is GCANRX

GCANRx is a clinical stage biopharmaceutical company focused on the development and commercialization of an innovative pharma-grade therapeutic that reduces disruptive symptoms in patient...

Read More

lock icon Get Full Access
map
  • 15 Walker Ave, Baltimore, Maryland, 33130, United States Headquarters: 15 Walker Ave, Baltimore, Maryland, 33130, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GCANRX

GCANRx Org Chart and Mapping

Employees
Motti Stenge

Motti Stenge

COO

See Full Org Chart arrow
email-formate-icon
View Email Formats for GCANRx
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding GCANRx

Answer: GCANRx's headquarters are located at 15 Walker Ave, Baltimore, Maryland, 33130, United States

Answer: GCANRx's official website is https://gcanrx.com

Answer: GCANRx's revenue is $5 Million to $10 Million

Answer: GCANRx's SIC: 2834

Answer: GCANRx's NAICS: 325412

Answer: GCANRx has 1-10 employees

Answer: GCANRx is in Biotechnology

Answer: GCANRx contact info: Phone number: Website: https://gcanrx.com

Answer: GCANRx is a clinical stage biopharmaceutical company focused on the development and commercialization of an innovative pharma-grade therapeutic that reduces disruptive symptoms in patients suffering from neuropsychiatric disorders without the side effects of existing medications. GCANRx has teamed up with a world renowned research center to treat 100 children diagnosed with ASD and related behavioral problems, with a combination of CBD, and additional proprietary compounds for up to 24 weeks. The purpose of the double-blind, placebo controlled study is to prove the efficacy of a new therapeutic in treating the core symptoms of Autism (ASD).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access